Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.
Angioimmunoblastic T-cell lymphoma (AITL) is a major type of peripheral T-cell lymphoma (PTCL). To elucidate the clinicopathologic characteristics and prognosis of AITL in Japan, we retrospectively analyzed 207 patients with AITL. The median patient age was 67 years (range, 34-91 years), with 73% of patients older than 60 years. With a median follow-up of 42 months in surviving patients, 3-year overall survival (OS) was 54% and progression-free survival (PFS) was 38%. The International Prognostic Index (IPI) and the prognostic index for PTCL, not otherwise specified (PIT) were predictive for OS in this analysis. Multivariate analysis found that age older than 60 years, elevated white blood cell (WBC) and IgA levels, the presence of anemia and thrombocytopenia, and extranodal involvement at > 1 site were significant prognostic factors for OS, and IgA, anemia, and mediastinal lymphadenopathy were significant prognostic factors for PFS. A novel prognostic model consisting of the prognostic factors for OS was successfully constructed. In conclusion, IPI and PIT were still useful for prognostication of AITL, and other factors, including those not used in IPI, such as IgA, anemia, WBC count, thrombocytopenia, and mediastinal lymphadenopathy, also significantly affected prognosis. Future investigations for IgA as a unique prognostic factor are warranted.
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi
T
Tokunaga
Kazuyuki
K
Shimada
Kazuhito
K
Yamamoto
Dai
D
Chihara
Takuji
T
Ichihashi
Rika
R
Oshima
Mitsune
M
Tanimoto
Toshihiro
T
Iwasaki
Atsushi
A
Isoda
Akira
A
Sakai
Hikaru
H
Kobayashi
Kunio
K
Kitamura
Kosei
K
Matsue
Masafumi
M
Taniwaki
Sadahiro
S
Tamashima
Yoshio
Y
Saburi
Taro
T
Masunari
Tomoki
T
Naoe
Shigeo
S
Nakamura
Tomohiro
T
Kinoshita
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000401:mortality; D007070:Immunoglobulin A / Q000097:blood*; D007150:Immunohistochemistry; D016130:Immunophenotyping; D007564:Japan; D053208:Kaplan-Meier Estimate; D016399:Lymphoma, T-Cell / Q000276:immunology* / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D007070:Immunoglobulin A